Abdulafeez (Deji) Oluyadi, PharmD: Agios Pharmaceuticals: Employment (full or part time) (Ongoing)
Learning Objectives:
Upon completion, participants will be able to describe the mechanism of action of mitapivat and its potential applications in sickle cell disease (SCD).
Upon completion, participants will be able to summarize the key findings and implications from the completed Phase 2 portion of the RISE UP study of mitapivat in SCD.
Upon completion, participants will be able to identify key design elements and objective of the ongoing Phase 3 portion of the RISE UP study of mitapivat in SCD and Phase 2 study of mitapivat in patients with SCD and nephropathy.